⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

January 10, 2022Journal of Clinical OncologyOpen Access

Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621

View Full Paper

Ask AI

Bookmark

Share

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

A 2022 study studied this question.

synapsesocial.com/papers/6a7ca5e580d29ce2cbfab46b https://doi.org/10.1200/jco.21.01693

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia2018 · 211 citations
2Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD222021 · 47 citations
3Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults2017 · 1,158 citations
4Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a<scp>CD</scp>22 monoclonal antibody2014 · 44 citations
5Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)2019 · 119 citations